bioAffinity Technologies, Inc. (BIAF) AI Stock Analysis

• Market Cap: $6.39M
• Dividend Yield: N/A
• Average Volume (3M): 5.91M
• Price to Earnings (P/E): ―
• Beta (1Y): -2.78
• Revenue Growth: -27.66%
• EPS Growth: 13.18%
• Country: US
• Employees: 57
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -4.74
• Shares Outstanding: 4,498,709
• 10 Day Avg. Volume: 6,249,809
• 30 Day Avg. Volume: 5,911,951
• PEG Ratio: 0.07
• Price to Book (P/B): 4.24
• Price to Sales (P/S): 1.18
• P/FCF Ratio: -1.50
• Enterprise Value/Market Cap: 1.06
• Enterprise Value/Revenue: 1.00
• Enterprise Value/Gross Profit: 4.17
• Enterprise Value/Ebitda: -0.48
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $1.50 ▲(16.28% Upside)

The score is held down primarily by weak financial performance (declining revenue, large losses, negative operating cash flow) and bearish technicals (below key moving averages with negative MACD). Corporate events provide some positives (accreditation/IP/compliance), but they are not yet strong enough to offset the core operating and trend weakness; valuation is also constrained by loss-making status and no dividend support.

Positive Factors

Strengthening patent portfolio

A US patent allowance plus a broad global portfolio (18 awarded, 33 pending) creates durable barriers to entry for CyPath® Lung. Strong IP supports exclusive commercial rights, improves licensing prospects, and underpins long-term revenue and partnership opportunities across diagnostics markets.

Laboratory accreditation and quality

Maintaining College of American Pathologists accreditation provides enduring clinical credibility and regulatory-aligned quality controls. This facilitates adoption by health systems, supports reimbursement discussions, and materially strengthens the trust needed for sustained commercial scaling in diagnostic services.

Early commercial adoption trend

A sustained, large increase in test volumes signals real clinical adoption of CyPath® Lung. Higher throughput can lower unit costs, enhance physician familiarity, and create referral momentum—structural factors that support durable revenue growth and potential margin improvement as volumes scale.

Negative Factors

Declining revenue and deep losses

Material, persistent revenue decline combined with severely negative margins indicates the core business is not yet generating sustainable profits. This undermines reinvestment capacity, increases reliance on external financing, and poses a long-term risk to executing commercialization and R&D plans.

Negative operating cash flow

Negative operating cash flow despite modest FCF growth suggests cash generation is weak and may be supported by non-operational items or timing. Persistent operating cash deficits strain liquidity, increase financing needs, and limit ability to fund commercialization, hiring, and capital investments long term.

Shareholder engagement/governance risk

An adjourned shareholder meeting for lack of quorum signals weak investor engagement or dispersed ownership, which can delay approvals for strategic initiatives and impair governance. Over time this raises execution risk for financing, M&A or board-driven initiatives critical to long-term strategy.

bioAffinity Technologies, Inc. Business Overview & Revenue Model

Company Description

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

How the Company Makes Money

bioAffinity Technologies generates revenue through multiple streams, primarily by commercializing its diagnostic and therapeutic products. This includes sales of its proprietary diagnostic tests to healthcare providers and institutions, as well as licensing agreements for its technologies to pharmaceutical companies. Additionally, the company may engage in partnerships with research institutions and biotech firms to co-develop new therapies, which can provide funding and shared revenue opportunities. Grants and funding from government and private entities for research and development projects also contribute to its earnings. Overall, the combination of product sales, licensing, and strategic partnerships forms the backbone of bioAffinity's revenue model.

bioAffinity Technologies, Inc. Financial Statement Overview

Summary

bioAffinity Technologies, Inc. faces significant financial challenges, with declining revenues and substantial losses. Negative profit margins and return on equity indicate poor financial health. Despite manageable leverage, negative cash flow and profitability metrics highlight the need for strategic improvements.

Income Statement

bioAffinity Technologies, Inc. has experienced a decline in revenue with a negative growth rate of -11.77% TTM, indicating challenges in maintaining sales momentum. The company also faces significant profitability issues, with a negative net profit margin of -152.17% and negative EBIT and EBITDA margins, reflecting operational inefficiencies and high expenses relative to revenue.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.31 TTM, suggesting manageable leverage. However, the return on equity is deeply negative at -930.20%, indicating that the company is not generating returns on shareholder investments. The equity ratio of 77.10% suggests a strong equity base relative to total assets, but the negative ROE is a significant concern.

Cash Flow

The cash flow statement reveals a slight improvement in free cash flow growth at 9.78% TTM, but the company still operates with negative operating cash flow, indicating cash management challenges. The free cash flow to net income ratio is slightly above 1, suggesting that the company is generating some cash relative to its net losses, but overall cash flow remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.78M	9.36M	2.53M	4.80K	0.00	0.00
Gross Profit	1.62M	3.38M	791.62K	4.34K	-4.82K	-22.24K
EBITDA	-14.11M	-8.33M	-7.63M	-5.61M	-5.32M	-6.86M
Net Income	-14.74M	-9.04M	-7.94M	-8.15M	-6.33M	-7.27M
Balance Sheet
Total Assets	11.55M	6.51M	8.22M	12.18M	1.45M	145.60K
Cash, Cash Equivalents and Short-Term Investments	7.67M	1.11M	2.82M	11.41M	1.36M	83.11K
Total Debt	680.95K	1.50M	1.58M	251.75K	11.36M	10.01M
Total Liabilities	2.64M	3.91M	3.37M	1.14M	17.24M	15.22M
Stockholders Equity	8.90M	2.60M	4.86M	11.04M	-15.79M	-15.07M
Cash Flow
Free Cash Flow	-8.51M	-7.34M	-6.06M	-4.29M	-2.05M	-2.21M
Operating Cash Flow	-8.45M	-7.26M	-6.04M	-4.07M	-2.05M	-2.21M
Investing Cash Flow	-60.57K	-79.08K	-2.21M	-219.99K	0.00	-2.89K
Financing Cash Flow	15.42M	5.63M	-344.98K	14.34M	3.33M	1.72M

bioAffinity Technologies, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.29
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIAF, the sentiment is Neutral. The current price of 1.29 is above the 20-day moving average (MA) of 1.25, below the 50-day MA of 1.51, and below the 200-day MA of 6.79, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 52.66 is Neutral, neither overbought nor oversold. The STOCH value of 47.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BIAF.

bioAffinity Technologies, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INBS	59 Neutral	$17.54M	-0.86	-223.45%	―	3.26%	65.96%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MYNZ	49 Neutral	$10.78M	―	―	―	―	―
BIAF	43 Neutral	$6.39M	-0.07	-245.18%	―	-27.66%	13.18%
NDRA	42 Neutral	$5.21M	-0.36	-236.34%	―	―	98.86%
ISPC	42 Neutral	$4.22M	-0.05	-296.20%	―	-67.73%	58.35%

bioAffinity Technologies, Inc. Corporate Events

bioAffinity Labs Maintain CAP Accreditation, Supporting CyPath Lung

On January 7, 2026, bioAffinity Technologies announced that its subsidiary Precision Pathology Laboratory Services in San Antonio successfully maintained its accreditation from the College of American Pathologists following a rigorous on-site inspection, reaffirming that the lab meets leading standards for quality, accuracy and patient safety. The CAP accreditation, viewed as the gold standard in laboratory quality, underpins the company’s CyPath® Lung test—designed to detect lung cancer as early as Stage 1A with clinical data showing 92% sensitivity and 87% specificity—and strengthens bioAffinity’s value proposition to physicians, health systems and partners as it seeks to grow revenue in a U.S. lung cancer diagnostics market estimated at $4.8 billion in 2024 and projected to more than double by 2034.

The most recent analyst rating on (BIAF) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Updates Village Oaks Physician Succession Agreement

On September 18, 2023, bioAffinity Technologies’ subsidiary Precision Pathology Laboratory Services consummated the acquisition of a San Antonio-based clinical anatomic and clinical pathology laboratory business from Village Oaks Pathology Services, with related governance structured through a succession agreement restricting the transfer of equity in Village Oaks’ professional entity to ensure continuity of designated physician ownership. In December 2025, Village Oaks’ sole shareholder, 77-year-old Dr. Roby P. Joyce, informed the company of his decision to transfer 100% of his equity in Village Oaks to long-serving pathologist Dr. James Humphreys, and on December 22, 2025, Village Oaks, PPLS and Dr. Humphreys entered into a new succession agreement that similarly restricts Humphreys from disposing of his equity without consent and establishes automatic transfer mechanisms and replacement procedures to maintain a qualified designated physician and preserve Village Oaks’ business operations, contracts, licenses and other rights.

The most recent analyst rating on (BIAF) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Adjourns Special Stockholder Meeting for Lack Quorum

On December 19, 2025, bioAffinity Technologies, Inc. convened but immediately adjourned a special meeting of stockholders after failing to reach a quorum, as an insufficient number of common shares were present in person or by proxy to conduct business. The special meeting has been rescheduled to reconvene on January 19, 2026, with the November 4, 2025 record date and all voting proposals unchanged, and previously submitted proxies remaining valid unless stockholders choose to alter their votes through the available proxy voting channels.

The most recent analyst rating on (BIAF) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Technologies to Present at Cancer Roundtable

On December 3, 2025, bioAffinity Technologies announced that it will present a poster at the American Cancer Society National Lung Cancer Roundtable on December 8, 2025. The poster highlights the successful use of CyPath® Lung, a noninvasive sputum-based flow cytometry test, in identifying Stage 1A lung cancer in patients with atypical presentations. This development underscores the test’s potential to provide clarity in complex diagnostic scenarios, potentially reducing the need for invasive procedures and improving early-stage lung cancer diagnosis.

The most recent analyst rating on (BIAF) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Technologies Reports Surge in CyPath® Lung Tests

On November 5, 2025, bioAffinity Technologies announced significant growth in the volume of their CyPath® Lung tests, with October’s test volume showing a 111% increase over the 2025 monthly average. This growth reflects the increasing recognition of the test’s clinical value by physicians and the success of the company’s outreach efforts to healthcare providers. The steady adoption of CyPath® Lung is seen as a step towards changing the standard of care in early lung cancer detection.

The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Technologies Secures Australian Patent for Lung Health

On October 28, 2025, bioAffinity Technologies announced that the Australian Patent Office accepted its patent application for a platform technology to assess lung health and predict multiple lung diseases. This acceptance strengthens bioAffinity’s global patent portfolio, enhancing its market positioning and protecting its core technology, which is crucial for the CyPath® Lung test and other diagnostics in development.

The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Technologies Presents at CHEST 2025 Conference

On October 20, 2025, bioAffinity Technologies announced its participation in CHEST 2025, where they will present research supporting the CyPath® Lung test’s methods for collecting and transporting patient samples. The study highlights the test’s ability to detect early-stage lung cancer with high sensitivity and specificity, potentially improving patient outcomes.

The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Technologies Secures Patent for Lung Cancer Detection

On October 16, 2025, bioAffinity Technologies, Inc. announced it received a notification of allowance from the United States Patent and Trademark Office for a patent titled ‘Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning.’ This patent covers a system and method for predicting lung cancer by analyzing patient sputum samples using an AI-built algorithm and flow cytometry platform. This development enhances bioAffinity’s intellectual property portfolio, which includes 18 awarded and 33 pending patents globally, and reinforces its position in the early-stage cancer diagnostics industry. The CyPath® Lung test, integral to this patent, offers high sensitivity and specificity in detecting early-stage lung cancer, potentially improving patient outcomes and reducing healthcare costs.

The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.